{"schema_version":"secwatch.filing_event.v1","accession":"0001639691-24-000139","form_type":"8-K","ticker":"LIVN","cik":"0001639691","company_name":"LivaNova PLC","filed_at":"2024-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.067920+00:00","generated_at":"2026-05-30T06:57:37.258309+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"CMS maintains VNS Therapy for DRE at Level 5 APC for 2025; LivaNova sees no business impact","bullets":["CMS announced on Nov 1, 2024 it will keep VNS Therapy for drug-resistant epilepsy at Level 5 Neurostimulator APC under the 2025 Medicare Hospital Outpatient PPS.","LivaNova says it is disappointed by the decision but does not expect any impact on its business.","The company plans to continue pursuing improved reimbursement for VNS Therapy for DRE."],"urls":{"canonical":"https://secwatch.observer/filing/0001639691-24-000139","json":"https://secwatch.observer/filing/0001639691-24-000139.json","markdown":"https://secwatch.observer/filing/0001639691-24-000139.md","text":"https://secwatch.observer/filing/0001639691-24-000139.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1639691/000163969124000139/0001639691-24-000139-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1639691/000163969124000139/livn-20241101.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T06:57:37.258309+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}